DEBIRI plus chemo vs. chemo alone for liver metastases
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests if a treatment called DEBIRI (tiny beads delivering chemo directly to the liver) plus standard chemotherapy works better than chemotherapy alone for colorectal cancer that has spread to the liver and can't be fully removed by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your colorectal cancer has spread to the liver, and doctors cannot remove all the liver tumors with surgery (or it's uncertain).
- You have not had chemotherapy for the cancer that spread to the liver.
- You are in generally good health (able to do daily activities).
- Your liver, kidneys, and blood counts are within acceptable ranges (will be checked by blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments for colorectal cancer that has spread to the liver: using tiny beads that deliver chemo directly to the tumor plus a liver infusion, versus the liver infusion alone. It aims to see which approach is safer and more effective.
This trial is testing a combination of treatments for a specific type of liver cancer (intrahepatic cholangiocarcinoma) that can't be removed surgically. The combination includes a liver-directed chemotherapy infusion, tiny beads that deliver chemo directly to the tumor, an immunotherapy drug (toripalimab), and a targeted therapy pill (lenvatinib). This approach aims to shrink the tumor and control the cancer for as long as possible.
This trial tests whether using chemotherapy beads delivered directly to the liver (DEB-TACE) before a living donor liver transplant improves outcomes for people with liver cancer. If you have a tumor in the right side of the liver that fits certain size and number limits, and you are already scheduled for a transplant, this study may be an option.
This trial tests a new way to treat advanced non-small cell lung cancer by combining two targeted interventional procedures: one puts tiny beads with chemo directly into the tumor (DEB-BACE), and the other uses an artery to deliver treatment (BAI). The goal is to shrink the tumor and improve symptoms.
This trial tests if giving a high dose of chemotherapy directly into the liver, followed by standard chemotherapy, is safe and works better than standard chemo alone for people with breast cancer that has spread mostly to the liver.
This trial tests whether a combination of two treatments—chemoembolization (DEB-TACE) plus chemotherapy given through the liver artery (RALOX-HAIC)—works better than chemoembolization alone for people with large liver cancer tumors (over 7 cm). The goal is to see if the combination shrinks tumors more effectively.
Hear when a new Liver Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.